ARCHIMEDES’ CEO DR. BRENDA MOTHERAL SELECTED AS 2023 WOMEN OF INFLUENCE WINNER. Nashville, TN, MONDAY, FEBRUARY 13, 2023 – Dr.…
ARCHIMEDES’ CEO DR. BRENDA MOTHERAL SELECTED AS 2023 WOMEN OF INFLUENCE WINNER. Nashville, TN, MONDAY, FEBRUARY 13, 2023 – Dr.…
Register to view our recent 20-minute webinar detailing the next evolution in employer benefits, specialty pharmacy carve-out. We are offering…
Specialty drug costs are growing at an unsustainable pace and increasingly pose a financial threat to the entire health care…
Archimedes is excited to share this snapshot of some key accomplishments from 2021.
BRENTWOOD, TN, August 10, 2021 – Archimedes, a recognized leader in specialty drug management solutions, announced the launch of MEDiQ,…
Archimedes’ specialty PBM carve-out program saved Wayne Farms 40% on their specialty spend in the first six months.
Does your PBM provide transparent contracts and reporting? It is time to move PBM business intelligence out of the dark ages. This white paper is the third in a series dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
Is your PBM applying rigorous clinical criteria to effectively identify and remove waste in your specialty drug benefit? Learn how misaligned coverage models and weak clinical criteria are working against plan sponsors. This white paper is the second of three dedicated to exploring best practices to help employers understand the challenges and opportunities in building a sustainable specialty drug benefit.
In collaboration with the Pacific Business Group on Health (PBGH), Archimedes identified over $50M in saving opportunities through biosimilar adoption of two large employers.
Update your browser to view this website correctly. Update my browser now